Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc32425246    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32425246  :  Publisher
PDF vom PMID32425246

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • Psychopharmacology of COVID-19 #MMPMID32425246
  • Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
  • Psychosomatics 2020[Sep]; 61 (5): 411-427 PMID32425246show ga
  • Background: With the rapid, global spread of severe acute respiratory syndrome coronavirus 2, hospitals have become inundated with patients suffering from coronavirus disease 2019. Consultation-liaison psychiatrists are actively involved in managing these patients and should familiarize themselves with how the virus and its proposed treatments can affect psychotropic management. The only Food and Drug Administration-approved drug to treat COVID-19 is remdesivir, and other off-label medications used include chloroquine and hydroxychloroquine, tocilizumab, lopinavir/ritonavir, favipiravir, convalescent plasma therapy, azithromycin, vitamin C, corticosteroids, interferon, and colchicine. Objective: To provide an overview of the major safety considerations relevant to clinicians who prescribe psychotropics to patients with COVID-19, both related to the illness and its proposed treatments. Methods: In this targeted review, we performed structured literature searches in PubMed to identify articles describing the impacts of COVID-19 on different organ systems, the neuropsychiatric adverse effects of treatments, and any potential drug interactions with psychotropics. The articles most relevant to this one were included. Results: COVID-19 impacts multiple organ systems, including gastrointestinal, renal, cardiovascular, pulmonary, immunological, and hematological systems. This may lead to pharmacokinetic changes that impact psychotropic medications and increase sensitivity to psychotropic-related adverse effects. In addition, several proposed treatments for COVID-19 have neuropsychiatric effects and potential interactions with commonly used psychotropics. Conclusions: Clinicians should be aware of the need to adjust existing psychotropics or avoid using certain medications in some patients with COVID-19. They should also be familiar with neuropsychiatric effects of medications being used to treat this disease. Further research is needed to identify strategies to manage psychiatric issues in this population.
  • |Adenosine Monophosphate/adverse effects/analogs & derivatives/therapeutic use[MESH]
  • |Adrenal Cortex Hormones/adverse effects/*therapeutic use[MESH]
  • |Alanine/adverse effects/analogs & derivatives/therapeutic use[MESH]
  • |Amides/adverse effects/therapeutic use[MESH]
  • |Anti-Inflammatory Agents/adverse effects/*therapeutic use[MESH]
  • |Antibodies, Monoclonal, Humanized/adverse effects/therapeutic use[MESH]
  • |Antiviral Agents/adverse effects/*therapeutic use[MESH]
  • |Ascorbic Acid/adverse effects/therapeutic use[MESH]
  • |Azithromycin/adverse effects/therapeutic use[MESH]
  • |Betacoronavirus[MESH]
  • |Chloroquine/adverse effects/therapeutic use[MESH]
  • |Colchicine/adverse effects/therapeutic use[MESH]
  • |Coronavirus Infections/complications/*drug therapy/metabolism/therapy[MESH]
  • |Drug Combinations[MESH]
  • |Drug Interactions[MESH]
  • |Humans[MESH]
  • |Hydroxychloroquine/adverse effects/therapeutic use[MESH]
  • |Immunization, Passive[MESH]
  • |Interferons/adverse effects/therapeutic use[MESH]
  • |Lopinavir/adverse effects/therapeutic use[MESH]
  • |Mental Disorders/chemically induced/complications/*drug therapy[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/complications/*drug therapy/metabolism[MESH]
  • |Psychotropic Drugs/adverse effects/metabolism/*therapeutic use[MESH]
  • |Pyrazines/adverse effects/therapeutic use[MESH]
  • |Ritonavir/adverse effects/therapeutic use[MESH]
  • |Vitamins/adverse effects/therapeutic use[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    411 5.61 2020